Premium
CA 19‐9 and carcinoembryonic antigen in pancreatic cancer diagnosis
Author(s) -
Favero Giuseppe Del,
Fabris Carlo,
Plebani Mario,
Panucci Aldo,
Piccoli Antonio,
Perobelli Laura,
Pedrazzoli Sergio,
Baccaglini Ugo,
Burlina Angelo,
Naccarato Remo
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860415)57:8<1576::aid-cncr2820570823>3.0.co;2-9
Subject(s) - carcinoembryonic antigen , medicine , immunoradiometric assay , pancreatic cancer , jaundice , monoclonal antibody , gastroenterology , ca19 9 , antigen , receiver operating characteristic , pancreas , predictive value , antibody , radioimmunoassay , cancer , pathology , immunology
CA 19‐9 (Centocor, Malvern, PA) and carcinoembryonic antigen (CEA), two recently developed immunoradiometric assays utilizing monoclonal antibodies, were evaluated in the sera of 139 subjects in order to assay their individual and combined value in pancreatic cancer diagnosis and to assess the influence of jaundice. Sensitivity, specificity, and accuracy in detecting pancreatic cancer were 69%, 85%, and 54% for CA 19‐9; and 28%, 78%, and 6% for CEA, respectively. Combined evaluation gave the highest specificity (95%) when both, and the highest sensitivity (79%) when at least one, gave pathologic results. The receiver‐operating characteristic curves demonstrated that CA 19‐9 is more discriminating than CEA, for any serum value. A correlation between serum bilirubin and CA 19‐9 was demonstrated in pancreatic and extrapancreatic disease. CEA determination, performed using monoclonal antibodies, seems to be unsatisfactory as compared to CA 19‐9 in pancreatic cancer diagnosis, and combined assessment does not improve the results of CA 19‐9 alone. Jaundice may influence serum CA 19‐9 in pancreatic and extra‐pancreatic diseases. Cancer 57:1576–1579, 1986.